 |
 |
 |
 |
 August 29, 2011Dale Zajicek appointed President of BioVectra Inc....read moreApril 19, 2011Doe & Ingalls and BioVectra Expand Partnership To Better Serve Biotech Companies...read moreJanuary 14, 2011BioVectra Expansion of cGMP Contract Fermentation Capacity Nears Completion...read more
|
|
| 
|
|
 |
|
|
|
Chronology |
 |
 |
- 1970
- Diagnostic Chemicals Limited (DCL) is incorporated by Dr. J. Regis Duffy, Dean of the Faculty of Science, University of Prince Edward Island
- 1976
- DCL opens its first manufacturing facility in the West Royalty Business Park, Charlottetown, PE
- 1982
- DCL opens its second facility in Charlottetown and extracts its first high purity enzymes
- 1983
- DCL (USA) is founded and is incorporated in Oxford, Connecticut
- 1991
- DCL adds its third and largest production/R&D facility, The Douglas J. Hennessy Biochemical Centre, to the West Royalty Business Park (28,000 square feet)
- 1991
- DCL is first selected as one of Canada's Top 100 Employers by Mediacorp Canada Inc.
- 1992
- DCL is awarded the "Canadian Award for Business Excellence"
- 1994
- DCL is first listed in "Atlantic Progress, The Top 101 Companies of Atlantic Canada"
- 1996
- Company is awarded ISO 9001:1994 Quality Standards accreditation
- 1996
- New 750 gallon Pfaudler reactor is installed; third production shift is initiated
- 1997
- New extraction plant is completed; operational 24 hours/day, 7 days/week
- 1997
- DCL adds fifth manufacturing facility in West Royalty Business Park, Charlottetown, PE
- 1998
- DCL expands its Research and Development activities
- 1999
- DCL is awarded Canada Export Award
- 2001
- Biochemical Division of DCL began operating under the name, BioVectra DCL
- 2002
- BioVectra DCL opens new biopharmaceutical manufacturing facility, The Regis and Joan Duffy Biopharmaceutical Centre, in the Charlottetown Airport Business Park, Charlottetown, PE (33,500 square feet)
- 2003
- BioVectra achieves FDA registration upon successful completion of audit, the cGMP facility was commissioned and validated in accordance with the ISPE protocols
- 2004
- BioVectra's completion of construction of 25,000 liter fermentation suite
- 2004
- BioVectra manufactures five drug products in facility during calendar year
- 2004
- BioVectra granted two Atlantic Innovation Fund (AIF) awards, first for taxane initiative and second for PEGylation initiative
- 2004
- Lorus announces Virulizin® commercial supply agreement with BioVectra DCL
- 2005
- FDA approval received on two drug products
- 2005
- Health Canada confirmation of establishment license
- 2006
- BioVectra DCL and the National Research Council Institute for Nutrisciences and Health announce research collaboration to identify new therapeutic candidates
- 2007
- BioVectra and Helix BioPharma Corp. sign manufacturing agreement to manufacture L-DOS47 bulk drug product for human clinical testing. L-DOS47 is a potential new drug product for lung cancer
- 2007
- BioVectra DCL (DCL's biochemical division) becomes incorporated and begins operating under BioVectra Inc. upon the sale of DCL's diagnostic division to Genzyme Corporation.
- 2008
- BioVectra awarded $3MM (AIF) to support partnering in development of new drug compounds
- 2008
- Kane Biotech Retains BioVectra to manufacture DispersinB™ to be used in the company's wound care product being developed for treating chronic wounds.
- 2008
- Doe & Ingalls of Maryland, LLC signs an exclusive agreement to distribute BioVectra Inc.'s bioprocessing reagents, molecular biology reagents and enzymes in the United States.
- 2008
- BioVectra Inc. and Taxolog, Inc. submission of the United States Drug Master File (DMF) for the manufacturing of the active pharmaceutical ingredient, Docetaxel.
- 2009
- BioVectra successfully completes the manufacturing of DispersinB® Topical Wound Gel under current Good Manufacturing Practices (cGMP) for Kane Biotech Inc.
- 2009
- BioVectra named as the number one innovation company in Atlantic Canada by Atlantic Progress magazine.
- 2009
- BioVectra and Oncolix Inc. announce manufacturing and investment agreement to produce Prolanta™, a targeted therapy for Breast Cancer.
- 2010
- BioVectra confirms partnership with Sandoz Inc. to market Docetaxel in the U.S.A.
- 2010
- BioVectra announces major investment in expanded custom synthesis and fermentation
|
 |
 |
|
